跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MVA-based vaccine
首页
药物
MVA-based vaccine
MVA-based vaccine
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES
EP 4153228 A4
申请人: HOPE CITY
优先权: 2020
CN
EP
US
WO
5 件公开
RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED VACCINE FOR THE AVIAN FLU
US 2011020391 A1
申请人: PAUL EHRLICH INST BUNDESAMT FUR SERA UND IMPFSTOFFE
优先权: 2006
CN
EP
US
3 件公开
METHODS OF ISOLATING POXVIRUSES FROM AVIAN CELL CULTURES
EP 4677076 A1
申请人: BAVARIAN NORDIC AS
优先权: 2023
EP
US
WO
3 件公开
PRODUCTION OF POXVIRUSES FROM QUAIL CELL CULTURES
EP 4677074 A1
申请人: BAVARIAN NORDIC AS
优先权: 2023
CN
EP
WO
3 件公开
Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
US 10576141 B2
申请人: BAVARIAN NORDIC AS
优先权: 2014
CN
US
3 件公开
UNIVERSAL INFLUENZA VACCINE BASED ON RECOMBINANT MODIFIED VACCINE ANKARA VIRUS (MVA)
US 2012141525 A1
申请人: JAIN RAJESH
优先权: 2009
CN
US
2 件公开
Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
US 11103570 B2
申请人: BAVARIAN NORDIC AS
优先权: 2015
CN
US
2 件公开
Shuttle vector for constructing recombinant MVA virus and having marker gene self-deleting system
CN 104975043 A
申请人: UNIV BEIJING TECHNOLOGY
优先权: 2015
CN
MVA-BASED VACCINE AGAINST COVID-19 EXPRESSING SARS-COV-2 ANTIGENS
EP 3928789 A1
申请人: CONSEJO SUPERIOR INVESTIGACION
优先权: 2020
EP
MVA-BASED VACCINE AGAINST COVID-19 EXPRESSING A PREFUSION-STABILIZED SARS-COV-2 S PROTEIN
EP 4108257 A1
申请人: CONSEJO SUPERIOR INVESTIGACION
优先权: 2021
EP
第 1 / 2 页
上一页
下一页
药物
反馈